pilepsy causes quality of life limitations similar to diabetes, cancer, heart disease, and arthritis. 1 There has been considerable effort from federal and nonfederal organizations to address this burden and assure that people live well with epilepsy, that is, with "no seizures, no side effects." 2 As part of this effort, the 2007 Quality Indicators for Epilepsy Treatment (QUIET) were developed to guide physicians on how to care for older persons with epilepsy. 3 Between 2001 and 2005, >250,000 Medicare beneficiaries 65 and older received care for epilepsy or seizures annually. 4 Medical care and treatment to assure seizure control are crucial in achieving optimal quality of life. 5 QUIET indicator 9 (QUI-ET-9) states that newly diagnosed older patients should not receive enzyme-inducing antiepileptic drugs (EI-AEDs), that is, phenytoin, carbamazepine, or phenobarbital, as first treatment for seizures given the current availability of better-tolerated AEDs. 6, 7 EI-AEDs interact with many common lipid and nonlipid soluble drugs with important clinical implications for an older patient. 7, 8 They are also associated with lower adherence and a higher risk of seizure recurrence compared with nonenzyme-inducing drugs. 9, 10 Despite that, studies of selected groups of older adults who had private insurance, or were in managed care plans, or received care from the Department of Veteran Affairs, showed that the use of EI-AED is pervasive with 50%-70% being prescribed EI-AEDs. 8, 9, 11, 12 However, a trend toward lower use was observed in the Veteran Affairs population. 12 The use of EI-AEDs and the concordance with QUIET-9 in the larger population of older American adults with epilepsy and drug coverage through Medicare part D is currently unknown. Medicare is the US federal health insurance program for people 65 years old or older, some Americans with disabilities or with end-stage renal disease. More than 90% of older Americans are Medicare beneficiaries: about half are enrolled in part D plans for drug prescription coverage. 13 Lower quality of care is of particular concern among minorities such as African Americans (AA) who have a higher prevalence of epilepsy. 4 Health care disparities between AA and whites with epilepsy are not uncommon: they have been reported for surgical interventions, 14,15 specialized care, 16 AED treatment, 17 and AED adherence. 10, 18 There is dearth of information on the quality of epilepsy care among other groups of Medicare beneficiaries. Hispanics were found to be less likely than whites to have access to specialized epilepsy care, 19 and Asians/Pacific Islanders less likely to pursue surgical epilepsy treatment compared with whites. 20 Moreover, Native American Medicare beneficiaries with epilepsy were less likely to receive neurology care compared with white beneficiaries. 21 Lack of access to neurologists could negatively impact the quality of AED treatment and, possibly, the control of seizures. 17 At present, data regarding AED use for the treatment of epilepsy in older Americans are limited, including data regarding the concordance of care with QUIET-9. This knowledge gap is especially pervasive in typically disadvantaged populations such as AA, Native Americans, and Hispanics. One objective of the current study was to investigate use of EI-AED in older adults with epilepsy of major racial/ethnic groups. In particular, we examined use among AA, Asians/Pacific Islander, Hispanic, American Indian/Alaska Native (AI/AN), and white older Medicare beneficiaries enrolled in Medicare part D plans. Our second objective was to examine concordance with the QUIET-9 indicator for new cases of epilepsy among racially/ethnically diverse older adults. Lastly, we examined whether QUIET-9 concordance differences by race/ ethnicity persisted after adjusting for various factors including patient-level factors such as age, comorbid conditions, or use of neurology care; socioeconomic factors such as indicators of poverty; and regional indicators to account for the geographic variability in medical care. In addition, we accounted for the part D benefit characteristics because the affordability of AEDs may vary depending on whether beneficiaries cover only part or all the cost of their prescription drugs.
MATERIALS AND METHODS
This study is a retrospective analysis of 2008-2010 administrative claims from the Center for Medicare and Medicaid Services and was reviewed and approved by the Institutional Review Board of the University of Alabama at Birmingham. Data were obtained for a 5% random sample of the Medicare overall older population (Fig. 1) . To increase representation of minority groups among epilepsy cases, we also obtained data on all AA, Asian/Pacific Islander, Hispanic, and AI/AN Medicare beneficiaries who had administrative claims for seizures and/or epilepsy (Fig. 1) . We restricted these populations to beneficiaries who were 67 years old or older and had Medicare part D coverage in 2009 (Fig. 1) .
To identify prevalent cases of epilepsy we used the following claim-based epilepsy diagnosis: (i) at least 1 claim (inpatient, outpatient or physician visit) with International Classification of Disease-version 9 (ICD-9) code 345.xx, or at least 2 claims with ICD-9 780.3x that were 30 days apart; and (ii) at least 1 AED prescription of 60 days or more. Claim-based diagnoses similar to this were found to have a positive predictive value of 94% for detecting cases of epilepsy among older veterans, 11 and 70%-88% in a managed care population. 22 We identified the index event as first claim that defined this diagnosis. Among the identified cases, we included beneficiaries who had at least 12 months of follow-up from the index event, that is, 12 months of Medicare part A (hospital insurance), B (coverage for outpatient and physician visits), and D (prescription drug coverage), and no managed care plans, or had coverage until death if death occurred within the 12-month follow-up.
We identified all filled brand and generic AED prescriptions, and subdivided them into EI-AED and non-EIAEDs. EI-AEDs were phenytoin, phenobarbital, carbamazepine, primidone, and the corresponding brand name drugs. We examined utilization of these AEDs by race/ethnic groups. Concordance of AED treatment with QUIET-9 was defined for new probable epilepsy cases which were cases with a period of 365 days before the index event with (i) continuous coverage with part A, B, and D; (ii) no claims with ICD-9 codes for epilepsy or seizures; and (iii) no prescriptions for AEDs (Fig. 1) . QUIET-9 indicates that "if newly diagnosed older patients are not on any AED therapy, they should not be started on EI-AEDs unless at least 2 other AEDs have been unsuccessful in stopping seizures or have intolerable side effects." 3 We, thus, identified the first and second consecutive AEDs prescribed after the clean period and in the 12-month follow-up. If beneficiaries filled prescriptions for a brand name drug and subsequently for the generic correspondent (or vice versa), only 1 drug was counted. A beneficiary was defined as having QUIET-9 concordant care if the first and second prescribed drugs were non-EI-AEDs.
Analysis
We obtained the frequency by race/ethnic group of EI-AED use and, among new cases, the frequency of QUIET-9 concordant care. The w 2 tests were used to test differences across beneficiaries' groups. In logistic regression, we examined whether differences by race/ethnicity in QUIET-9 concordant care for new cases were significant after adjusting for factors that we specified a priori as potential confounders of this association. We controlled for: (1) individual factors-age, sex, number of comorbid conditions, and neurology visit close to index event, that is at least 1 claim for a neurologist or neurosurgeon visit in the 30 days before to the 60 days after the index event; (2) socioeconomic factors-being eligible for part D low income subsidy (LIS), ZIP code level poverty indicators, and part D benefit phases defined for the drug prescribed right before the first observed AED prescription. In 2009-2010, these phases were, in order of occurrence, deductible, copayment/ coinsurance (beneficiaries pay a copayment or coinsurance for covered prescription drugs), coverage gap (donut hole: beneficiaries, depending on the plans, pay the full cost of prescription drugs), and catastrophic coverage (Medicare covers most of prescription drug cost); and (3) geography: US region of residence (Northeast, West, Midwest, and South). Comorbidities were identified in the 1 year before the index event using algorithms based on the Charlson Comorbidity score. 23, 24 ZIP code level information on poverty was obtained from the 2010 Census. We created an indicator for high poverty corresponding to ZIP codes where >20% of households lived below 100% of the federal poverty line.
RESULTS
Among the 36,912 cases of epilepsy in 2009, 19.2% were white, 62.5% AA, 11.3% Hispanic, 5.0% Asian, and 2.0% AI/AN (Table 1) . Moreover, 61.6% were female, 22.4% 85 years old and older, and 50.3% were from the southern United States. A substantial proportion, 46.0%, had 4 or more comorbidities in the year before the index event and only about 36% saw a neurologist close to the index event. Moreover, 82.0% were eligible for the part D LIS. Of the new cases, 59.8% had QUIET-9 concordant treatment, from 71% for Asians to 54.8% of AI/ANs (P < 0.0001, unadjusted analyses) ( Table 2 ). In adjusted analyses (Table 3) , differences between white beneficiaries and other race/ethnic groups were not significant: odds ratios and confidence intervals (CI) compared with white beneficiaries were: for AA 0.81, CI, 0.66-1.00, for Hispanics 0.92, CI, 0.70-1.12, for Asians 1.39, CI, 0.99-1.96, and for AI/AN 0.93, CI, 0.55-1.57 (Table 3) .
Some differences were noticed across sociodemographic factors (Table 3) . Beneficiaries who were male, were in the part D deductible phase, did not reside in the Northeast, or lived in high poverty ZIP codes were less likely to have QUIET-9 concordant care than their counterparts (Table 3) . Beneficiaries who saw a neurologist during the follow-up were more likely to have QUIET-9 concordant care than those who did not see a neurologist (Table 3 ).
DISCUSSION
The current consensus on the treatment of older adults with epilepsy is to avoid EI-AEDs unless other drugs are tried and found to not control seizures or to give intolerable side effects (QUIET-9 indicator). We find that 2 of 3 Medicare beneficiaries with epilepsy were still treated with EI-AEDs in 2009. Among those who may be considered new cases of epilepsy (defined as having no seizures or AED in the previous 1 y), only about 60% received treatment concordant with the QUIET-9 indicator according to which newly diagnosed older patients should not receive EI-AEDs as first line of treatment for seizures. Differences across race/ ethnic groups in QUIET-9 concordant care, especially difference for African Americans and AI/ANs compared with whites, were significant only in analyses that did not account for socioeconomic factors. Among older Americans with epilepsy, the utilization of EI-AEDs is still common. Such utilization, although lower, is still surprisingly high among those who may be starting AED treatment for the first time. The consequences for seizure control or side effects in this Medicare population are currently unknown and deserve scrutiny. Moreover, the reasons why physicians may start older patients on such drugs also deserve attention. Many factors influence the AED choice including better familiarity with some AEDs and epilepsy syndromes. 5 As this familiarity may depend on the level of training, 5 it is not surprising to find that the use of EI-AEDs was lower and concordance with QUIET-9 was higher among cases who had neurology encounters. Others have also shown how the setting of care may influence epilepsy treatment. 17 However, even among new probable epilepsy cases with neurology care, more than a third did not have drug treatment concordant with QUIET-9. It may be that an EI-AED was prescribed by non-neurologists and later changed by the neurologist. In support of this explanation, we found that beneficiaries who saw neurologists were more likely to fill prescriptions for >1 AED in the follow-up period compared with those who did not see a neurologist (26.6% vs. 18.3%). Moreover, comparing new cases with and without neurological care close to the index event, we found that those who do not see a neurologist were more likely to be AA, eligible for LIS, reside in the southern US, and to live in high poverty ZIP code areas. Thus, while our analysis adjusted for these factors, there may be other unmeasured underlying access to care issues that may explain why they do not receive neurological care or treatment concordant with the QUIET-9 indicator. However, it is also plausible that neurologists believe older drugs like phenytoin to be efficacious and to have other useful properties. 12 Disparities in epilepsy care have been reported for several treatment options. 10, 14, [17] [18] [19] [20] 25 In our study, some racial disparities were evident in the concordance of AED treatment to the QUIET-9 indicator, in particular for AA and AI/ANs. The latter group was previously found to be less likely to receive neurological care. 21 Similarly in our study, only about half of new AI/AN epilepsy cases had 1 or more encounters with neurologists in the few months around the diagnosis period. This may explain the lower frequency of QUIET-9 concordant care among probable new AI/AN cases, as having neurologist visits was associated with a higher likelihood of such care. The disparity between AA and AI/ANs and whites was not significant in our model adjusted for a number of potential confounders including socioeconomic factors such as area level poverty indicators. EI-AEDs are older drugs that are less expensive than newer non-EI drugs: therefore, it was not surprising that poverty was associated with a lower likelihood of QUIET-9 concordant care.
Our results on the drug plan benefit phase are interesting. The association of higher cost-sharing on the utilization of drugs and adherence to treatment are well known. [26] [27] [28] [29] [30] [31] [32] [33] [34] In line with this literature, we found that being in the deductible phase, when beneficiaries pay for prescriptions out of their own pocket, was associated with a lower likelihood of having QUIET-9 concordant care compared with being in cost-sharing part D phases or in the coverage gap (donut hole), another non-cost-sharing phase in which prescriptions are paid out of pocket by beneficiaries after having reached a predetermined level of drug expenditures. In the coverage gap, however, beneficiaries may have alternative drug plans, or they may have reached this benefit phase because they used more expensive AEDs. Research also shows that drug choices are sensitive to whether patients expect to reach annual limits on drug coverage. 32 Here, once the coverage gap is reached, the AED choice is not affected by the fact that beneficiaries are responsible for its cost, while this choice may be more sensitive during the deductible phase. These results, together with the significant findings about poverty indicators, bring to light the implications of drug coverage restrictions and low socioeconomic status on appropriate AED treatment, and ultimately on epilepsy outcomes. Further research is warranted on the outcomes in low socioeconomic populations with epilepsy, and on how to assure affordable and effective epilepsy care.
Some limitations of our study are noted. First, there are limitations associated with studying health care utilization based on claims data. Epilepsy cases that may have not needed medical attention or follow-up may be missed when using claims data. Even when care is received and claims are available, claim-based epilepsy identification algorithms have limitations. However, we used a method more conservative than published algorithms that have positive predictive values >90%. Second, the identification of new cases is limited. Cases may have had claims for epilepsy or seizures in the years before the one we used as the clean period. In a previous study that used a similar epilepsy definition except for the requirement to be on AEDs and for a clean period of 2 years, the estimated epilepsy incidence was reduced by 10% if such clean period was increased by 1 year. 4 Therefore, some of what we consider new cases may have tried non-EI-AEDs before the clean period and, thus, be misclassified as not having QUIET-9 concordant care in 2009. If this is the case, we have underestimated the proportion of new cases with concordant treatment. Furthermore, some cases may not have been classified as new cases because they used AEDs (eg, gabapentin) in the year before the index event, but for reasons other than epilepsy. Among cases who did not have claims for seizure or epilepsy diagnosis in the year before the index event and who either had no AEDs or were on AEDs that may have been prescribed for reasons other than epilepsy, we found that only 28% used EI-AEDs in 2009, and 75% had treatment concordant with QUIET-9. Third, there is a possibility that part D data are incomplete, for example due to low-cost programs for generic drugs such as $4 30-day prescriptions at Walmart or other such stores. Recent studies, however, found that only a small proportion of prescriptions (about 6%) are not adjudicated in part D, 35 and that the validity of part D data is not compromised by the existence of low-cost programs for generic drugs. 36 Moreover, Pauly et al 37 found that only 8% of prescriptions available for low-cost programs were purchased through such program: this figure was lower for anticonvulsants that include AEDs. In addition, the authors found no difference by race in users of low cost programs. Fourth, we restricted to a population who had Medicare coverage for a one year period or until death. When we applied this restriction, we retained about 84% of the white and about 75% of the minority population. Considering the results on poverty and part D coverage found in this study, the excluded population may be less likely to have QUIET-9 concordant care, and thus, we may have overestimated the proportion of new cases with QUIET-9 concordant care especially among minorities. Fifth, results may not be generalizable to the larger Medicare population as we restricted to a population with fee for service Medicare and on part D. Other part D beneficiaries may be on managed care plans for which administrative claims are not available and for whom we could not have determined epilepsy status. Moreover, because of our research question, our cohort over-represented minority groups compared with a random sample of Medicare beneficiaries meeting similar inclusion criteria. 38 Despite its limitations, this study is one of the largest epilepsy investigations to focus on older minorities with epilepsy in the United States. This large cohort allowed us to examine AED utilization and concordance with current consensus on epilepsy treatment among older Americans of several racial/ethnic groups who received care for epilepsy or seizures in 2009. It is a first glance at AED utilization in this population, and at whether treatment is in line with what is deemed acceptable to minimize the occurrence of seizures and side effects. Although no significant racial/ethnic disparities in AED treatment were found, potential socioeconomic disparities exist that highlight the need to monitor epilepsy care in older Americans who may have a lower opportunity to live well with epilepsy. Further research should also investigate the implications on epilepsy outcomes of receiving care that is concordant (or not) with the current understanding of optimal treatment for older Americans with epilepsy.
